How to Get Your Doctor to Prescribe Wegovy

Getting a Wegovy prescription starts with meeting the clinical criteria and having a direct conversation with your doctor about weight management as a medical issue. Wegovy (semaglutide 2.4 mg) is FDA-approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. If you meet those thresholds, the conversation is less about convincing your doctor and more about initiating it in the right way, because research shows that how the topic of weight comes up in a medical visit shapes everything that follows.

Who Actually Prescribes These Medications

You do not need to see a specialist to get a Wegovy prescription. The vast majority of obesity medication prescriptions come from primary care physicians, internists, and advanced practice providers such as nurse practitioners and physician assistants. A longitudinal study tracking prescription patterns from 2017 through early 2024 found that primary care physicians and internists wrote about half of all obesity medication prescriptions, while advanced practice providers accounted for roughly 40 percent, a share that had grown substantially over that period. Endocrinologists, cardiologists, and surgeons together accounted for a small fraction.¹

This means your regular doctor or nurse practitioner is likely the right starting point. You do not need a referral to an obesity medicine specialist, though seeing one is an option if your primary care provider is uncomfortable managing the medication. Primary care plays a central role in obesity management, though reviews have noted that some primary care clinicians feel undertrained in newer pharmacotherapies and may not be fully up to date on how medications like GLP-1 receptor agonists fit into broader care.² If your doctor seems hesitant or unfamiliar with the medication, that is worth noting as a signal to seek a second opinion or ask for a referral rather than assume you do not qualify.

How to Bring Up Weight at Your Appointment

Many people feel awkward raising weight with their doctor, and doctors often feel the same awkwardness in reverse. Research on how weight-loss counseling actually gets initiated in primary care visits found that the conversation tends to go better when patients frame weight as one of their reasons for the visit or explicitly ask for help. On the clinician side, the conversation flows more naturally when the doctor can connect weight to an existing medical problem rather than raising it in isolation.³

In practical terms, this means you are more likely to have a productive conversation if you list weight management as one of your agenda items when you check in, rather than hoping it comes up organically. If you already have a related condition on your chart, connecting the dots for your doctor can help. Saying something like “I’d like to talk about whether a weight-loss medication could help with my blood pressure” gives the clinician a medical framework to work within, which research shows makes them more likely to engage with the topic seriously.

The tone your doctor uses in response matters too. A study examining how clinicians frame weight-related referrals found that when providers presented a weight management program as good news or an opportunity, patients were far more likely to follow through compared to when the same referral was framed around the harms of obesity. The “good news” framing was associated with better attendance and more weight loss, while the “bad news” approach produced no measurable benefit over a neutral tone.⁴ If your doctor responds to your request in a way that feels shaming or dismissive, that is not just unpleasant, it is clinically counterproductive. You are allowed to find a provider whose approach works for you.

What Your Doctor Will Evaluate Before Prescribing

Assuming you meet the BMI criteria, your doctor will not simply hand you a prescription and send you on your way. Wegovy belongs to a class of drugs called GLP-1 receptor agonists, and prescribing guidelines call for screening based on your individual risk factors. A narrative review of adverse events with these medications concluded that prescribing decisions should account for gastrointestinal tolerability, kidney function and dehydration risk, gallbladder history, retinopathy risk if you have diabetes, and whether you are at risk for excessive muscle loss.⁵

You should expect your doctor to ask about or check for several things before writing the prescription:

Gallbladder problems: GLP-1 medications are linked to an increased risk of gallstone-related issues, so a history of gallbladder disease may affect the decision.
Thyroid history: Semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies. A personal or family history of medullary thyroid carcinoma or a rare condition called Multiple Endocrine Neoplasia syndrome type 2 is a contraindication.
Pancreatitis: A history of pancreatitis will likely make your doctor more cautious or steer toward a different treatment.
Kidney function: The nausea, vomiting, and diarrhea that can accompany these drugs raise dehydration concerns, which can worsen kidney problems.
Muscle mass: If you are older or already have low muscle mass, your doctor may want to discuss strategies to preserve lean tissue during weight loss, since significant weight loss from any cause tends to include some muscle.

Bringing your medical history to the appointment, including any relevant family history, helps your doctor move through this evaluation efficiently. If you have none of these risk factors, the screening is straightforward. If you do have one or more, it does not automatically disqualify you but will shape the monitoring plan.

The Dose Escalation Schedule and Why People Struggle With It

Wegovy is not a medication you start at full dose. The FDA-approved protocol begins at 0.25 mg per week for the first month, then steps up through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg. Each step is supposed to last about four weeks, meaning it takes roughly four to five months to reach the target dose. This gradual ramp is designed to reduce gastrointestinal side effects, which are the most common reason people struggle early on.

In practice, many people do not follow this timeline cleanly. An analysis of commercially insured adults starting semaglutide for weight management found that most deviated from the recommended monthly dose-escalation schedule within the first five months. By month five, close to half had stopped the medication entirely. Discontinuation was strongly tied to cost: people with the highest monthly copays were considerably more likely to stop than those with the lowest.⁶

This means you should go into the process with eyes open about two things. First, the early weeks may involve nausea, and your doctor can help manage that with timing adjustments, dietary changes, or slower escalation. Second, the financial piece is a real barrier, not a minor inconvenience. Asking your doctor’s office about prior authorization requirements, manufacturer savings programs, and your specific plan’s formulary coverage before you start is more productive than finding out at the pharmacy counter.

Insurance Coverage and the Medicare Question

One of the biggest barriers to getting Wegovy is not clinical but financial. Many commercial insurance plans cover it but require prior authorization, which means your doctor’s office will need to submit documentation showing you meet the criteria. Some plans require evidence that you have tried and failed other weight-loss approaches first, such as a supervised diet program or another medication. Your doctor is accustomed to navigating these requirements, so ask directly what your insurer needs.

For people on Medicare, the landscape shifted when the FDA approved Wegovy for a cardiovascular indication, specifically reducing the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. Medicare has historically been prohibited from covering weight-loss drugs, but this new cardiovascular indication opened a pathway. A KFF analysis estimated that about 3.6 million Medicare beneficiaries had both established cardiovascular disease and obesity or overweight, potentially making them eligible for coverage under this indication. Of those, roughly 1.9 million also had diabetes and may have already been eligible for GLP-1 coverage through that diagnosis.⁷

If you are on Medicare and want Wegovy specifically for weight loss without an established cardiovascular disease diagnosis, coverage remains limited. Your doctor may be able to help you explore whether you qualify under the cardiovascular indication or whether other GLP-1 medications covered for diabetes management could be appropriate.

Why Your Doctor Will Talk About Lifestyle Changes Too

When you ask for Wegovy, your doctor will almost certainly also talk about diet, exercise, and behavioral strategies. This is not a deflection or a way to avoid prescribing. Clinical guidelines recommend multicomponent therapy that combines medication with nutritional and behavioral support, though the use of these combined approaches alongside GLP-1 medications has not been widespread in practice.⁸

There is a practical reason for this beyond the clinical guidelines. GLP-1 medications reduce appetite significantly, and people on them often eat substantially less without trying. That makes it important to ensure the food you do eat is nutritionally adequate. Protein intake in particular matters for preserving muscle mass during rapid weight loss. Your doctor or a dietitian can help you plan around the reduced appetite rather than just letting it run unchecked. Think of the lifestyle conversation as a complement to the medication, not a prerequisite that replaces it.

Understanding That This Is Long-Term Treatment

One of the most important things to understand before starting Wegovy is that obesity is treated as a chronic condition in current medical thinking, meaning the medication is not designed as a short course you take until you hit a target weight and then stop. The evidence on what happens after stopping is clear and consistent. In the STEP 1 trial extension, participants who withdrew from semaglutide 2.4 mg regained about two-thirds of the weight they had lost within one year of stopping, and the improvements they had seen in blood pressure, cholesterol, and blood sugar reversed in parallel.⁹

This pattern has been confirmed across multiple trials. A review of withdrawal data from several GLP-1 studies concluded that the weight regain seen after stopping is best understood as disease recurrence rather than treatment failure, similar to how blood pressure returns when someone stops taking an antihypertensive. The body’s weight-regulation mechanisms reassert themselves once the medication is removed.¹⁰

This matters for your conversation with your doctor because it reframes the commitment. You are not asking for a one-time fix. You are asking to start a medication that works well while you take it and that you may need to continue indefinitely, with all the cost and logistical implications that carries. Being upfront about your understanding of this timeline signals to your doctor that you have realistic expectations, which makes them more likely to view you as a good candidate for the prescription.

Why Compounded Versions Are a Risk

If cost or supply shortages push you toward compounded semaglutide from a compounding pharmacy rather than the brand-name product, your doctor will likely push back, and the data supports their concern. A pharmacovigilance analysis using the FDA’s adverse event reporting system found that compounded GLP-1 formulations were associated with higher rates of several adverse events compared to FDA-approved versions, including higher reporting odds for abdominal pain, diarrhea, nausea, cholecystitis, and suicidality. The compounded products also showed dramatically higher rates of preparation errors, prescribing errors, and contamination issues. Hospitalization odds were more than twice as high for compounded products.¹¹

Compounded medications are not generics. They are mixed by pharmacies that are not held to the same manufacturing standards as the companies producing the FDA-approved drug. The contamination and preparation error signals in the data are particularly concerning because they represent problems with the product itself, not just the predictable side effects of the active ingredient. If your doctor declines to prescribe a compounded version, they are protecting you, not gatekeeping.

What If Your Doctor Says No

There are legitimate clinical reasons a doctor might decline to prescribe Wegovy. You might not meet the BMI criteria, you might have a contraindication, or your doctor might believe a different medication is better suited to your situation. Other FDA-approved options for weight management exist, including tirzepatide (Zepbound), which acts on two receptor pathways instead of one, and liraglutide (Saxenda), a daily injectable GLP-1 that is generally considered less potent than semaglutide but may be appropriate for some people. Orlistat and a naltrexone-bupropion combination (Contrave) are older oral options that work through entirely different mechanisms.

But sometimes the refusal is not clinical. Some doctors remain uncomfortable prescribing weight-loss medications because of outdated views about obesity, a belief that willpower should be sufficient, or unfamiliarity with the evidence base. Weight bias in healthcare settings is well-documented and can compromise the quality of care, create psychological distress, and lead patients to avoid seeking help at all.¹²

If you feel your doctor is dismissing your request based on stigma rather than clinical judgment, you have several options. Ask for the specific clinical reason for the refusal. Request a referral to an obesity medicine specialist. Seek a second opinion from another primary care provider or from a telehealth platform that specializes in weight management. You are not being difficult by advocating for evidence-based treatment.

Preparing for Your Appointment

Walking into the appointment prepared makes the conversation more efficient and signals that you have done your homework. Before you go, gather the following:

Your weight history: Previous diet attempts, prior medications, any medically supervised programs you have completed. Many insurers want documentation of prior efforts.
Related conditions: A list of any diagnoses that qualify as weight-related comorbidities, such as hypertension, sleep apnea, type 2 diabetes, high cholesterol, or joint problems.
Insurance details: Your plan’s formulary, any prior authorization requirements, and whether your plan has a preferred GLP-1 medication. Some plans cover tirzepatide but not semaglutide, or vice versa.
Family history: Particularly thyroid cancer or pancreatitis, since these affect whether semaglutide is appropriate.

You do not need to walk in with a detailed medical argument. But having your records organized and your question clear, something like “I meet the BMI criteria and I’d like to discuss whether Wegovy or a similar medication is appropriate for me,” sets the right tone. Your doctor evaluates clinical candidates every day. Making it easy for them to say yes involves removing logistical friction, not performing persuasion.

When Telehealth Is a Reasonable Path

The growth of telehealth platforms specializing in weight management has changed the landscape for people who struggle to get these prescriptions through traditional channels. These services typically employ physicians or nurse practitioners who are comfortable with obesity pharmacotherapy and can prescribe, manage dose escalation, and handle prior authorization. Given that advanced practice providers now write a substantial and growing share of obesity medication prescriptions, this shift toward non-traditional care settings is consistent with where the field is moving.¹

Telehealth is not a workaround for bypassing legitimate medical screening. Reputable platforms still require medical history, lab work, and ongoing monitoring. But for someone whose local primary care provider is unfamiliar with GLP-1 prescribing or whose in-person visits are limited, a telehealth obesity medicine provider can fill the gap. Just verify that the platform uses licensed providers in your state, prescribes FDA-approved medications rather than compounded versions, and provides continuity of care rather than one-off prescriptions with no follow-up.